Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

Tanabe Pharma Corporation

Status and phase: Completed; Phase 2

Conditions: Hepatitis C

Treatments: Drug: MP-424 (Telaprevir)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00621296

G060-A7

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.

Enrollment: 15 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with genotype 1b chronic hepatitis C
• Patients naive to the concomitant medications with interferon

Exclusion criteria

• Patients diagnosed with decompensated cirrhosis
• Patients diagnosed with positive HBs antigen in the test

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

MP-424

Experimental group

Treatment:

Drug: MP-424 (Telaprevir)